Extended distribution agreement with Rogg Verbandstoffe in Germany

(Tromsø, 18 July 2017) Biotec Pharmacon’s (”Biotec”, OSE: BIOTEC) subsidiary Biotec Betaglucans AS has extended the distribution agreement for Woulgan in Germany with Rogg Verbandstoffe (Rogg) for an additional 12 months with automatic renewal thereafter Svein Lien, CEO of Biotec Pharmacon ASA says: -We are very pleased to extend this agreement, providing our customers with … Continued ›

Memo fra CEO, Svein Lien

Kjære aksjonærer På grunn av mange forespørsler tilknyttet diverse diskusjonsforum og sosiale medier, er det besluttet at jeg som administrerende direktør skal gi en personlig redegjørelse som forhåpentligvis rydder opp i noen av uklarhetene som presenteres og diskuteres. Jeg bringer ikke ny informasjon i det følgende, men presenterer det i en ny kontekst som kanskje … Continued ›

Biotec appeals UK Drug Tariff rejection

Biotec Pharmacon ASA’s (”Biotec”, OSE: BIOTEC) subsidiary Biotec BetaGlucans has today filed an appeal for rejection of UK Drug Tariff reimbursement With support from external advisors, Biotec has evaluated the decision by the Drug Tariff authority under NHS to reject the application for remuneration of Woulgan for wound treatment in UK, and concluded that there … Continued ›

Patent on technology platform SBG granted Biotec Pharmacon in the US

Biotec Pharmacon ASA (OSE: BIOTEC)  has been granted patent in the US for the technology platform of gel forming Soluble Beta-Glucan (SBG). The granted patent US 9,623,043 title of invention: Glucan. The claims cover the method for producing a gel forming SBG and the product obtainable by this method as well as the medical use … Continued ›

UK Drug Tariff rejects current Woulgan application

Biotec Pharmacon ASA’s (”Biotec”, OSE: BIOTEC) subsidiary Biotec Betaglucan has received negative feedback from UK Drug Tariff regarding application for reimbursement. The UK Drug Tariff has in a letter of May 2nd informed Biotec Pharmacon that the NHS has decided not to list Woulgan based on its current application because they consider the evidence provided … Continued ›

Woulgan® Gel registered as a Class 1 exempt by the FDA in the USA

Biotec Pharmacon ASA’s (”Biotec”, OSE: BIOTEC) subsidiary Biotec Betaglucans has received positive confirmation by the FDA that Woulgan® Gel is listed as a Class 1 exempt in the USA Woulgan® Gel is registered as a Class 1 exempt by the FDA in the USA. This means that Woulgan® can be imported and used in the country. … Continued ›

Norwegian Minister of Trade and Industry Monica Mæland visits Biotec Pharmacon

The Norwegian Minister of Trade and Industry has today visited Tromsø, to get feedback and to learn about the biotechnology activities of the Biotech North Cluster and to meet some of the local biotech companies. She also visited Biotec Pharmacon’s production facilities to see the company’s operation. “We are very pleased that Mrs Mæland took … Continued ›

Publication in Journal of Wound Care

Woulgan was recently featured in a scientific article in Journal of Wound Care:   Clinical evaluation of a bioactive beta-glucan gel in the treatment of ‘hard-to-heal’ wounds”. “The aim of this evaluation is to assess the effects of a wound healing gel in a wounds of different  aetiologies. Data was recorded on the wound surface area, tissue type, … Continued ›